NCT04302025 2026-03-06A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Genentech, Inc.Phase 2 Recruiting99 enrolled
NCT06008119 2025-09-18Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerShanghai Kechow Pharma, Inc.Phase 3 Recruiting165 enrolled